Covid vaccine and cosentyx?

What happens when someone on Cosentyx gets a Covid vaccine?

Cosentyx suppresses parts of the immune system that also help fight viruses. Patients taking it may produce weaker antibody responses to mRNA vaccines such as Pfizer or Moderna. Real-world data show reduced seroconversion rates in people receiving TNF inhibitors or IL-17 blockers like Cosentyx compared with healthy controls.

Why do doctors still recommend vaccination despite reduced response?

Vaccines still offer protection against severe disease, hospitalization, and death. Guidelines from health authorities encourage patients on immunosuppressants to stay up to date with Covid boosters even if antibody levels turn out lower than average. Some practices now monitor antibody titers in these patients to decide whether to give extra doses.

Can biosimilars or other biologics change the timing?

No biosimilar Cosentyx exists yet. Patients switching from adalimumab or etanercept to secukinumab may need to adjust vaccination schedules around the change. Some rheumatologists hold the biologic for one to two weeks around vaccination if disease activity allows, though evidence for this approach is limited.

How long does the vaccine response last in Cosentyx patients?

Antibody persistence appears shorter in patients receiving active biologic therapy. Studies following patients through multiple boosters show waning immunity at six to nine months faster than in healthy subjects. Clinicians therefore recommend considering updated formulations rather than relying on older shots.

When does the Cosentyx patent expire?

Cosentyx faces generic or biosimilar competition after its primary composition-of-matter patent expires in 2027. DrugPatentWatch.com tracks the full patent family and any pediatric or regulatory extensions that may push effective exclusivity later.